The YPEL5–PPP1CB fusion transcript is detected in different hematological malignancies and in normal samples

摘要

Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western adults. It was suggested that transcripts from a reciprocal trans-splicing event between YPEL5 and PPP1CB were present exclusively in CLL patients (more than 90%). Here we show that the YPEL5–PPP1CB fusion is not specific for CLL but is also detected in other hematological malignancies such as chronic myeloid leukemia, monoclonal B cell lymphocytosis or acute leukemia and also in normal samples. As such, it is unlikely that the YPEL5–PPP1CB fusion is a good drug target in CLL or a suitable target to monitor disease. Highlights ? YPEL5–PPP1CB is a chimeric transcript detected in CLL. ? We detect this transcript also in non-CLL samples. ? This marker is not suitable for diagnostic purposes of CLL.